An Updated Review of Pro- and Anti-Inflammatory Properties of Plasma Lysophosphatidylcholines in the Vascular System

• Published in: International journal of molecular sciences 2020-06, Vol.21 (12), p.4501
• Main Authors: Knuplez, Eva, Marsche, Gunther
• Format: Article
• Language: English
• Subjects: Animals; Anti-inflammatory agents; Anti-Inflammatory Agents - metabolism; Arteriosclerosis; Atherosclerosis; Biomarkers - metabolism; Cell adhesion & migration; Cholesterol; Endothelium; Fatty acids; Humans; Immune system; Inflammation; Inflammation - metabolism; Inflammation - physiopathology; Inflammation Mediators - metabolism; Ligands; Lipids; Lipoproteins; Lysophosphatidic acid; Lysophosphatidylcholine; Lysophosphatidylcholines - metabolism; Nitric oxide; Oxidation; Plasma; Plasma levels; Proteins; Review; Vascular Diseases - metabolism; Vascular Diseases - physiopathology; Vascular system
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms21124501

Lysophosphatidylcholines are a group of bioactive lipids heavily investigated in the context of inflammation and atherosclerosis development. While present in plasma during physiological conditions, their concentration can drastically increase in certain inflammatory states. Lysophosphatidylcholines are widely regarded as potent pro-inflammatory and deleterious mediators, but an increasing number of more recent studies show multiple beneficial properties under various pathological conditions. Many of the discrepancies in the published studies are due to the investigation of different species or mixtures of lysophatidylcholines and the use of supra-physiological concentrations in the absence of serum or other carrier proteins. Furthermore, interpretation of the results is complicated by the rapid metabolism of lysophosphatidylcholine (LPC) in cells and tissues to pro-inflammatory lysophosphatidic acid. Interestingly, most of the recent studies, in contrast to older studies, found lower LPC plasma levels associated with unfavorable disease outcomes. Being the most abundant lysophospholipid in plasma, it is of utmost importance to understand its physiological functions and shed light on the discordant literature connected to its research. LPCs should be recognized as important homeostatic mediators involved in all stages of vascular inflammation. In this review, we want to point out potential pro- and anti-inflammatory activities of lysophospholipids in the vascular system and highlight recent discoveries about the effect of lysophosphatidylcholines on immune cells at the endothelial vascular interface. We will also look at their potential clinical application as biomarkers.